Recently approved heart drug poses potential risk to brain, eye, researcher warns

Patients with mild heart failure stand to benefit from a new drug that can halt the progression of their disease and reduce their risk of cardiovascular-related death. But the drug -- a tablet that combines the agents valsartan and sacubitril, sold under the trade name Entresto by drugmaker Novartis -- may be too good to be true, warns one expert.

from Today's Healthcare News -- ScienceDaily http://ift.tt/1QbigTl